Septerna Inc
- SEPN
- NASDAQ
- Biotechnology
- GPCR-targeted Small Molecules
- Endocrinology/Metabolic Drugs
$36.38
Today +0.08%Quote Oct 19, 2026, 08:00 PM UTC
−5.97%over the last month
Max drawdown −11.7%From 1-month high −9.9%3 months +8.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Septerna
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
123
Founded
2019
Market value
$1.70B
Quote Oct 19
Floor
$34.30
5.7% below price
Resistance
$36.41
0.1% above price
Price vs analyst targets
9 analysts
Lowest target
$43.00Highest target
$60.00
$43.00Highest target
$60.00
- Price $36.38
- Average target $50.40
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 39% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SEPNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free